Allergan 3Q09

3Q Revenues: $1.1 billion (+4%)

3Q Earnings: $179.2 million (+8%)

YTD Revenues: $3.3 billion (-2%)

YTD Earnings: $401.1 million (-4%)

Comments: Specialty pharmaceuticals sales were up 8% in the quarter to $940.6 million, while medical devices sales were down 11% to $187.2 million. Botox/Neuromodulator sales were $327.8 million (+3%). Eye Care Pharmaceuticals revenue was $535.1 million (+5%). Skin Care revenue was $62.9 million (+136%). Urologics revenue was $14.8 million (-13%).

News from our sister sites